CERO THERAPEUTICS HOLDINGS, INC.

CERO Therapeutics Holdings, Inc., trading under the ticker PBAX on Nasdaq, is the successor entity to Phoenix Biotech Acquisition Corp, a blank-check company that completed its initial public offering in 2021 with a focus on the life sciences and biotechnology sector. Sponsored by Phoenix Biotech Sponsor, LLC, the vehicle targeted innovative therapeutics companies and announced a business combination with Cero Therapeutics, a clinical-stage biopharmaceutical company developing engineered chimeric engulfment receptor T-cell therapies for cancer. The 10-Q filing dated May 13, 2022, reflects the SPAC's quarterly reporting obligations during the period leading up to the close of that transaction. Investors and analysts tracking SPAC deal flow, clinical-stage biotech de-SPAC activity, and sponsor histories can access the full data set for PBAX and thousands of comparable vehicles by signing up for SpacDesk at spacdesk.com.